GeneCode receives record Parkinson’s funding
European Innovation Council Accelerator finances treatment development drive for condition
Read More
Tag: parkinson’s
Hope for Parkinson’s disease and Lewy body dementia patients
Research into modified RNA messages could help treat diseases and develop new therapies
Read More
Michael J. Fox Foundation funding boost for Newel Health’s Soturi
Next phase of Newel Health’s digital therapeutics solution for Parkinson’s disease gains vital grant
Read More
Biogen, Sangamo team up on neurological diseases
The companies have detailed plans to leverage Sangamo’s proprietary zinc finger protein (ZFP) technology.
Read More
Could gut bacteria guard against Parkinson’s?
The results are the latest in a number of recent studies which have found a link between brain function and the digestive system.
Read More
Genetic Parkinson’s cohorts ‘urgently’ need identifying
Only half of patients who are diagnosed as young onset patients are offered a genetic test on diagnosis.
Read More
Bayer acquires BlueRock in cell therapy move
After the acquisition, Bayer will own full rights to BlueRock Therapeutics’ CELL+GENE platform.
Read More
Neuraxpharm launches first products in UK
It has also announced the appointment of the company’s new general manager, Craig Bowen.
Read More
Parkinson’s UK to inject £1m into drug development
The charity is partnering with NRG Therapeutics Ltd to discover and develop a potential drug that could safeguard dopamine cells.
Read More
PhoreMost, C4X Discovery announce neurodegeneration collaboration
The collaboration will initially accelerate C4X Discovery’s Parkinson’s disease drug discovery pipeline.
Read More
£1.5million investment in Parkinson’s drug discovery
Parkinson’s UK says it intends to invest a further £1.5 million into its drug discovery programme aiming to develop novel gene transcription modulators for Parkinson’s.
Read More
Keapstone satisfies conditions for further £1m investment
Virtual biotech Keapstone Therapeutics is in line for a further £1 million investment from Parkinson’s UK to move forward its innovative disease-modifying therapeutic approach to motor neuron disease (MND) and Parkinson’s.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
